Evotec shows weak June performance, analyst consensus points above current shares
Published on 06/23/2026 at 12:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 12:51.
Evotec (DE0005664809) opens this Tuesday with weak recent share performance while trading on Xetra and regional German venues. Consensus data show the biotech stock changing hands clearly below the average analyst price target.
What the consensus implies
On wallstreet-online, Evotec shares are quoted around 4.59 euros on 23 June, leaving the stock roughly 42 percent below the 52-week high and about 16 percent above the 52-week low. The one-year performance stands at approximately minus 30 percent on this data set.
According to the same overview, 31 analysts cover Evotec, with an average price target of about 8.45 euros per share. This implies an upside of roughly 85 percent versus the current level, even after a monthly decline of more than 12 percent in June.
How analysts and traders view the stock
Finanzen.net shows Evotec shares at 4.59 euros on the Stuttgart exchange at mid-morning, a day-on-day move of around minus 0.7 percent. The site also highlights estimates and expectations for the stock, confirming a cautious near-term picture despite the higher average target.
For the US-traded Evotec ADR (ticker EVO on NASDAQ), TradingKey reports a closing price of 2.64 US dollars on 22 June, up just over 3 percent for that session. The technical dashboard there classifies the overall signal as Sell based on moving averages, with six sell and no buy signals on the MA5 to MA200 set.
Background and price data on Evotec
Key news, estimates and trading data on the Evotec shares are collected on the dedicated topic page and in the company’s investor-relations section.
How Evotec earns its money
Evotec develops and operates research alliances and development partnerships for new drug candidates, working with global pharma and biotech companies. The business is structured into EVT Execute, which provides integrated discovery and development services, and EVT Innovate, which advances proprietary and co-owned therapeutic projects.
Where Evotec shares trade now
The Evotec shares (DE0005664809) trade on 2026-06-23, 10:32, on German venues around 4.59 euros per share, based on wallstreet-online and finanzen.net indications.
Key data on the Evotec shares
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Xetra
- Price (as of 2026-06-23, 10:32): 4.59 EUR
- Market cap: 0.94 billion EUR (as of 2026-06-22)
- Sector / industry: Biotechnology & Medical Research
- Index membership: not in DAX family benchmark indices
- Next earnings date: not officially scheduled
This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
